Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

IperionX (NASDAQ:IPX) Stock Jumps 6.4% - Should You Buy?

IperionX logo with Materials background
Image from MarketBeat Media, LLC.

Key Points

IperionX Limited Sponsored ADR (NASDAQ:IPX - Get Free Report) rose 6.4% during mid-day trading on Tuesday. The company traded as high as $14.04 and last traded at $13.90. Approximately 29,612 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 275,239 shares. The stock had previously closed at $13.06.

Analyst Upgrades and Downgrades

Several research analysts recently commented on IPX shares. Roth Capital set a $53.00 target price on shares of IperionX in a report on Wednesday, August 5th. B. Riley Financial decreased their target price on shares of IperionX from $52.00 to $34.00 and set a "buy" rating for the company in a research report on Wednesday, September 30th. Jefferies Financial Group initiated coverage on shares of IperionX in a research note on Wednesday, September 2nd. They issued a "buy" rating and a $26.00 price target on the stock. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of IperionX in a research report on Thursday, October 15th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $42.00.

View Our Latest Report on IPX

IperionX Trading Up 10.0%

The stock's fifty day moving average price is $18.56 and its 200-day moving average price is $31.04. The company has a quick ratio of 2.95, a current ratio of 3.24 and a debt-to-equity ratio of 0.04.

IperionX (NASDAQ:IPX - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.50) EPS for the quarter. As a group, equities analysts forecast that IperionX Limited Sponsored ADR will post -0.13 earnings per share for the current year.

Institutional Trading of IperionX

A number of hedge funds have recently modified their holdings of IPX. GAMMA Investing LLC increased its stake in shares of IperionX by 40.3% during the second quarter. GAMMA Investing LLC now owns 1,681 shares of the company's stock worth $50,000 after purchasing an additional 483 shares during the period. Connective Capital Management LLC acquired a new position in IperionX in the 2nd quarter valued at $160,000. DLD Asset Management LP bought a new position in IperionX during the 1st quarter worth $260,000. Finally, Private Advisor Group LLC increased its position in IperionX by 69.9% during the 1st quarter. Private Advisor Group LLC now owns 63,111 shares of the company's stock worth $1,643,000 after buying an additional 25,964 shares during the period. Institutional investors and hedge funds own 2.76% of the company's stock.

IperionX Company Profile

(Get Free Report)

IperionX Limited NASDAQ: IPX is a critical minerals and advanced materials company focused on producing low-carbon titanium products in the United States. The company is developing domestic sources of titanium minerals and technologies intended to convert titanium feedstocks into titanium metal, powder and other advanced materials.

IperionX's primary development asset is the Titan Project in Tennessee, which contains titanium, zircon and other heavy mineral sands. The company is also developing proprietary processing technologies, including the Hydrogen-Assisted Metallothermic Reduction (HAMR) process and the Titanium Alloy Production (TAP) process, with the goal of manufacturing titanium products using less energy than conventional production methods and incorporating recycled titanium where practical.

The company targets customers in industries such as aerospace, defense, medical devices, automotive, consumer products and additive manufacturing.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in IperionX Right Now?

Before you consider IperionX, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IperionX wasn't on the list.

While IperionX currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines